Last updated on May 2020

Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis


Brief description of study

A Phase 2a, multicenter, 3-part, randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and PK of once-daily treatment with PLN-74809 in participants with idiopathic pulmonary fibrosis.

Detailed Study Description

Three part study:

Part A - 4 week treatment period evaluating PLN-74809 or matching placebo

Part B - 12 week treatment period evaluating PLN-74809 or matching placebo

Part C - 12 week treatment period evaluating up to two higher PLN-74809 dose cohorts or matching placebo

Clinical Study Identifier: NCT04396756

Find a site near you

Start Over

St. Luke's Hospital

Chesterfield, MO United States
  Connect »

Clinical Site

Toronto, ON Canada
  Connect »

Clinical Site

Windsor, ON Canada
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.